Drugs / Vandetanib
Vandetanib
also known as
ZD6474 · Zactima · CAPRELSA · AZD6474 · Caprelsa(R) · GNF-PF-2188 · NSC-744325 · NSC-760766 · +3 more
Small molecule targets EGFR, KDR, PTK6, RET, SRC, TEK via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed medullary thyroid gland carcinoma 2 milestones | |||||
| Filed | EU (EMA) | — | medullary thyroid gland carcinoma | 2010-09-23 | “AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the...” astrazeneca.com ↗ |
| Filed | US (FDA) | — | medullary thyroid gland carcinoma | 2010-09-23 | “AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the...” astrazeneca.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (2) | US (FDA) | CAPRELSA | — | 2018-10-12 – 2024-03-07 | fda.gov ↗ |
| Approved | EU (EMA) | Caprelsa | — | 2012-02-16 | europa.eu ↗ |
| Approved | US (FDA) | CAPRELSA | — | 2011-04-06 | fda.gov ↗ |
Trials 102 · started per year
today
US approved 2011
EU approved 2012
3
2
3
5
15
18
20
8
2
1
8
4
6
3
2
1
1
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03291379 | May 2017 → Aug 2019 | colorectal cancer, hepatocellular carcinoma | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 136 trials | ||||||
| Phase 1 | NCT01941849 | Oct 2014 → Dec 2015 | paraganglioma, pheochromocytoma | University College, London | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01582191 | May 2012 → Oct 2025 | metastatic malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01544140 | Apr → Jul 2012 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01561781 | Mar → Jul 2012 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01551615 | Mar → Jun 2012 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01539655 | Feb → Sep 2012 | medullary thyroid gland carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01586624 | Jan 2012 → Jun 2020 | non-small cell lung carcinoma | Cancer Research UK | Completed | No outcome recorded |
| Phase 1 | NCT01004419 | Nov 2009 → Nov 2010 | non-small cell lung carcinoma | University of Wisconsin, Madison | Withdrawn | No outcome recorded |
| Phase 1 | NCT00996723 | Oct 2009 → Apr 2012 | diffuse intrinsic pontine glioma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00807170 | May 2009 → Aug 2010 | non-small cell lung carcinoma | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00660725 | Feb 2009 → Nov 2010 | high grade malignant neoplasm | Leonard Appleman | Completed | No outcome recorded |
| Phase 1 | NCT00745732 | Oct 2008 → Sep 2012 | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00732745 | Oct 2008 → Jun 2010 | esophageal cancer, gastroesophageal junction adenocarcinoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00821080 | Oct 2008 → Feb 2015 | glioblastoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00937417 | Sep 2008 → Sep 2009 | breast cancer, head and neck cancer, lung cancer, prostate cancer | SWOG Cancer Research Network | Withdrawn | No outcome recorded |
| Phase 1 | NCT01183559 | Aug 2008 → Nov 2010 | esophageal cancer, gastric cancer, gastroesophageal junction adenocarcinoma | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00667147 | Mar 2008 → May 2012 | cancer | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT00734890 | Mar 2008 → Jun 2010 | lung cancer, lymphoma, lymphoproliferative syndrome, small intestine cancer | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00613223 | Feb 2008 → Oct 2010 | gliosarcoma | Annick Desjardins | Completed | No outcome recorded |
| Phase 1 | NCT00601614 | Jan 2008 → Jan 2010 | cancer of unknown primary site | Mayo Clinic | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00613054 | Nov 2007 → Mar 2009 | gliosarcoma | Annick Desjardins | Completed | No outcome recorded |
| Phase 1 | NCT00551096 | Oct 2007 → May 2013 | biliary tract cancer, malignant pancreatic neoplasm | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT00533169 | Sep 2007 → Feb 2011 | neuroblastoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00496665 | Jul 2007 → Aug 2008 | breast cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00472017 | Apr 2007 → Oct 2011 | central nervous system neoplasm | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00822887 | Mar 2007 → May 2010 | malignant glioma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT00436072 | Feb 2007 → Feb 2012 | colorectal cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00450138 | Dec 2006 → Nov 2009 | head and neck cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00503711 | Sep 2006 → Nov 2007 | cancer | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00496275 | Aug 2006 → May 2007 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00496509 | Aug 2006 → Oct 2007 | colorectal cancer | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00532909 | Jul 2006 → May 2010 | colorectal cancer | Branimir Sikic | Completed | No outcome recorded |
| Phase 1 | NCT00272350 | Dec 2005 → Feb 2014 | high grade astrocytic tumor, low grade glioma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00499850 | Aug 2005 → Jun 2006 | colorectal adenocarcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00507091 | Aug 2005 → May 2006 | adenocarcinoma, colorectal cancer, metastatic malignant neoplasm | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1 | NCT00506051 | Jul 2005 → May 2006 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT02495103 | Aug 2015 → Feb 2020 | leiomyomatosis, renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT01661179 | Nov 2012 → Dec 2013 | medullary thyroid gland carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 1/2 | NCT00862836 | Apr 2009 → Sep 2010 | ovarian carcinoma | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
| Phase 1/2 | NCT00923247 | Feb 2009 → Apr 2016 | medullary thyroid gland carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00514046 | Jul 2007 → Dec 2019 | medullary thyroid gland carcinoma, multiple endocrine neoplasia type 2A, multiple endocrine neoplasia type 2B | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00441142 | May 2007 → Aug 2013 | gliosarcoma | Patrick Y. Wen, MD | Completed | No outcome recorded |
| Phase 251 trials · 4 met primary · 8 missed | ||||||
| Phase 2 | NCT06482086 | Jun 2021 → Dec 2024 overdue | thyroid gland carcinoma | West China Hospital | Recruiting | Met primary |
| Phase 2 | NCT03630120 | Aug 2018 → Nov 2019 | medullary thyroid gland carcinoma, poorly differentiated thyroid gland carcinoma, thyroid gland papillary carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02788201 | Mar 2017 → Oct 2019 | urinary bladder cancer, urothelial carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02638428 | Dec 2015 → Dec 2021 | childhood acute myeloid leukemia | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02530411 | Apr 2015 → Dec 2018 | neoplasm | Velindre NHS Trust | Unknown | Missed primary |
| Phase 2 | NCT01823068 | Nov → Dec 2014 | non-small cell lung carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02142036 | May 2014 → Aug 2018 | metastatic malignant neoplasm | Oslo University Hospital | Completed | Met primary |
| Phase 2 | NCT02117167 | Apr 2014 → Dec 2018 | non-small cell lung carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 2 | NCT02299999 | Apr 2014 → Dec 2022 overdue | breast cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02015065 | Dec 2013 → May 2016 | gastrointestinal stromal tumor | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01934335 | Oct 2013 → Dec 2018 | invasive breast carcinoma | Ronald Weigel | Terminated | Missed primary |
| Phase 2 | NCT01414426 | Jan 2012 → Jan 2019 | precancerous condition, verrucous carcinoma of oral cavity | University of Chicago | Completed | No outcome recorded |
| Phase 2 | NCT01601808 | Oct 2011 → Sep 2018 | malignant pancreatic neoplasm | University of Liverpool | Completed | No outcome recorded |
| Phase 2 | NCT01191892 | Jun 2010 → Dec 2015 | renal pelvis/ureter urothelial carcinoma, ureter cancer, urethra cancer, urinary bladder cancer | Cardiff University | Completed | No outcome recorded |
| Phase 2 | NCT00872989 | Mar 2010 → Oct 2013 | fallopian tube cancer, ovarian carcinoma, primary peritoneal carcinoma | SWOG Cancer Research Network | Completed | Missed primary |
| Phase 2 | NCT00811369 | Aug 2009 → Oct 2012 | breast cancer | Ontario Clinical Oncology Group (OCOG) | Completed | No outcome recorded |
| Phase 2 | NCT00757692 | Jan 2009 → Feb 2012 | prostate cancer | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2 | NCT00752986 | Dec 2008 → Sep 2013 | female breast carcinoma | Genzyme, a Sanofi Company | Terminated | No outcome recorded |
| Phase 2 | NCT00720083 | Nov 2008 → Aug 2011 | head and neck cancer | Radiation Therapy Oncology Group | Terminated | No outcome recorded |
| Phase 2 | NCT00753675 | Oct 2008 → Sep 2012 | carcinoma of the ampulla of vater, gallbladder cancer | Genzyme, a Sanofi Company | Completed | Missed primary |
| Phase 2 | NCT00777179 | Oct 2008 → Jan 2010 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00753714 | Oct 2008 → Apr 2011 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00686036 | May 2008 → Apr 2010 | prostate cancer | Genzyme, a Sanofi Company | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00683787 | May 2008 → Apr 2009 | gastric cancer | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00566995 | Feb 2008 → Jun 2014 | kidney cancer, von Hippel-Lindau disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00659438 | Feb 2008 → Nov 2010 | prostate cancer | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00481845 | Jan 2008 → Dec 2009 | breast cancer | Stanford University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00613626 | Jan 2008 → Aug 2015 | small cell lung carcinoma | Hoosier Cancer Research Network | Completed | Missed primary |
| Phase 2 | NCT01372813 | Dec 2007 → Jun 2010 | clear cell renal carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00597116 | Dec 2007 → Jan 2010 | malignant mesothelioma | Genzyme, a Sanofi Company | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00537095 | Sep 2007 → Dec 2009 | thyroid tumor | Genzyme, a Sanofi Company | Completed | Met primary |
| Phase 2 | NCT00459121 | Jul 2007 → Jan 2008 | lung cancer | Barbara Ann Karmanos Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00508001 | Jul 2007 → Nov 2008 | hepatocellular carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00454116 | Mar 2007 → Mar 2008 | colorectal cancer | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00500292 | Mar 2007 → Mar 2008 | colorectal cancer | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00445549 | Jan 2007 → Dec 2008 | fallopian tube neoplasm, ovarian neoplasm, peritoneal neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00410189 | Nov 2006 → Mar 2013 | lung cancer | M.D. Anderson Cancer Center | Completed | Met primary |
| Phase 2 | NCT00402896 | Oct 2006 → Jun 2014 | lung cancer | M.D. Anderson Cancer Center | Terminated | Missed primary Stop: Enrollment |
| Phase 2 | NCT00880334 | Sep 2006 → Dec 2013 | transitional cell carcinoma, urinary bladder cancer | Dana-Farber Cancer Institute | Completed | Missed primary |
| Phase 2 | NCT00358956 | Aug 2006 → Jan 2008 | thyroid cancer | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00290537 | Jan 2006 → Apr 2008 | lung cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00494481 | Jan 2006 → Jun 2007 | female breast carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00498797 | Dec 2005 → Jul 2007 | hormone-resistant prostate carcinoma, metastatic prostate carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00252746 | Dec 2004 → Jan 2007 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00098345 | Nov 2004 → Feb 2008 | thyroid cancer | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00071188 | Feb 2004 → Oct 2007 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00059722 | May 2003 → Jun 2007 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00066313 | May 2003 → Dec 2006 | lung cancer | Genzyme, a Sanofi Company | Completed | Missed primary |
| Phase 2 | NCT00047788 | Oct 2002 → May 2004 | plasma cell myeloma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00047840 | Oct 2002 → Sep 2006 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00034918 | May 2002 → Nov 2003 | breast neoplasm, metastatic neoplasm | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 36 trials · 3 met primary · 2 missed | ||||||
| Phase 3 | NCT01876784 | Sep 2013 → Aug 2015 | differentiated thyroid carcinoma | Genzyme, a Sanofi Company | Completed | Missed primary |
| Phase 3 | NCT00418886 | Jan 2007 → Sep 2008 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | Missed primary |
| Phase 3 | NCT00410761 | Nov 2006 → Jul 2009 | thyroid cancer | Genzyme, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00404924 | Nov 2006 → Oct 2009 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00364351 | Aug 2006 → Sep 2008 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT00312377 | May 2006 → Aug 2008 | non-small cell lung carcinoma | Genzyme, a Sanofi Company | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT02239952 | Nov 2014 → Nov 2021 | malignant glioma | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| — | NCT02013089 | Dec 2013 → May 2017 | digestive system cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT00681798 Comparator | Jul 2006 → Jun 2009 | pancreatic ductal adenocarcinoma | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00995007 Comparator | Sep 2009 → Jun 2015 | anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00687297 Comparator | Apr 2008 → Jan 2011 | non-small cell lung carcinoma | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 2 | NCT00459043 Comparator | Mar 2007 → Mar 2010 | head and neck squamous cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT04760288 Comparator | Nov 2023 → Oct 2027 | medullary thyroid gland carcinoma | Hoffmann-La Roche | Withdrawn | No outcome recorded |
| Phase 3 | NCT04211337 Comparator | Feb 2020 → May 2023 overdue | medullary thyroid gland carcinoma | Loxo Oncology, Inc. | Active not recruiting | Met primary |
| Phase 3 | NCT01298323 Background | Feb 2011 → Apr 2013 | medullary thyroid gland carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01496313 Comparator | Jun 2012 → Apr 2014 | thyroid cancer | Sanofi | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2012-02-21 | AstraZeneca | Regulatory European Commission approves CAPRELSA® (vandetanib) for patients with advanced medullary thyroid cancer astrazeneca.com ↗
AstraZeneca today announced that the European Commission has granted marketing authorisation for CAPRELSA® (vandetanib) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
| 2011-11-18 | AstraZeneca | Regulatory CAPRELSA™ (vandetanib) receives positive CHMP opinion in the European Union for treating advanced medullary thyroid cancer astrazeneca.com ↗
AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. |
| 2011-04-07 | AstraZeneca | Regulatory FDA approves orphan drug vandetanib astrazeneca.com ↗
AstraZeneca today announced that the US Food and Drug Administration (FDA) approved the orphan drug vandetanib |
| 2011-01-07 | AstraZeneca | Regulatory US Food and Drug Administration extend review timeline for vandetanib new drug application astrazeneca.com ↗
AstraZeneca announced today that the US Food and Drug Administration (FDA) has extended the time to complete its review of the New Drug Application (NDA) for the investigational drug vandetanib. |
| 2010-12-02 | AstraZeneca | Regulatory US FDA Advisory Committee Makes Recommendation on New Drug Application for Vandetanib in Advanced Medullary Thyroid Cancer astrazeneca.com ↗
The Committee acknowledged that there are patients with MTC in which the risk-benefit profile of vandetanib was acceptable, and voted 10 to 0 in favour of a post-approval study requirement to evaluate other doses. |
| 2010-09-23 | AstraZeneca | Regulatory US and EU regulatory submissions for VANDETANIB in advanced medullary thyroid cancer accepted for review astrazeneca.com ↗
AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). |
| 2009-10-28 | AstraZeneca | Regulatory AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC astrazeneca.com ↗
AstraZeneca announced today that it has withdrawn the regulatory submissions for the use of ZACTIMA (vandetanib) 100mg in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) from the US FDA and the European Medicines Agency (EMEA). |
All press releases naming this drug 8 releases
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 114 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vandetanib | “Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.” PMID 22701615 ↗ Jun 201289“BTG-002814 (containing 100 mg vandetanib) delivered transarterially, 7 to 21 days before surgery” PMID 31579027 ↗ Oct 2019 “Tretinoin, Vandetanib, Vemurafenib” NCT02788201 ↗ “ZD6474 (vandetanib) 100mg” NCT00507091 ↗ “ZD6474 (vandetanib) 100mg” NCT00496509 ↗ “Drug: ZD6474 (vandetanib)” NCT00450138 ↗ “ZD6474 (vandetanib) 100mg” NCT00252746 ↗ “ZD6474(Vandetanib) 300 mg” NCT00508001 ↗ “ZD6474 (vandetanib)” NCT00098345 ↗ “ZD6474 (vandetanib)” NCT00499850 ↗ “ZD6474 (vandetanib)” NCT00358956 ↗ |
| Known as | AZD6474 | “A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)” NCT01586624 ↗ |
| Known as | CAPRELSA | “A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of Vandetanib (CAPRELSA) in Healthy Subjects when a Single Oral Dose of Vandetanib 300 mg...” NCT01539655 ↗4“A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Subjects When Administered Alone and in Combination with...” NCT01544140 ↗ “with a Single Dose of Vandetanib (CAPRELSA) 300 mg” NCT01561781 ↗ “Vandetanib (CAPRELSA) 800 mg” NCT01551615 ↗ “Caprelsa (vandetanib)” NCT01601808 ↗ |
| Known as | Caprelsa(R) | “Phase II Trial of Vandetanib (ZD6474, Caprelsa(R) in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors” NCT02015065 ↗ |
| Known as | GNF-PF-2188 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24828 ↗ |
| Known as | NSC-744325 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24828 ↗ |
| Known as | NSC-760766 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24828 ↗ |
| Known as | SAR390530 | “Vandetanib (SAR390530)” NCT01876784 ↗ |
| Known as | Vandetanib - Zactima (ZD 6474) | “Vandetanib - Zactima (ZD 6474)” NCT00613223 ↗ |
| Known as | Zactima | “Vandetanib (ZACTIMA; ZD6474; AstraZeneca) is an oral small molecule antineoplastic drug that inhibits vascular endothelial growth factor receptor 2 (VEGFR2), estimated...” NCT02015065 ↗9“A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or...” NCT00923247 ↗ “This study will examine the effectiveness of an investigational drug called ZD6474 (also known as vandetanib or ZACTIMA).” NCT00566995 ↗ “This study uses the drugs Abraxane (also called ABI-007) and Vandetanib (also called Zactima and ZD6474).” NCT00667147 ↗ “ZD6474 (Zactima) 100mg” NCT00496509 ↗ “Zactima (vandetanib)” NCT00498797 ↗ “Zactima (ZD6474)” NCT00496275 ↗ |
| Known as | ZD-64 | ChEMBL registry synonym — accepted as the source's own label CHEMBL24828 ↗ |
| Known as | ZD6474 | “A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca...” NCT01876784 ↗42“Vandetanib (CAPRELSA; ZD6474) potently inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), and shows additional inhibitory activity at sub-micromolar...” NCT00923247 ↗ “Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian...” NCT00872989 ↗ “This was a parallel group, randomized, double blind, placebo controlled, multicentre study designed to assess whether vandetanib (ZD6474) conferred an improvement in PFS as...” NCT00537095 ↗ “Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas” NCT00734890 ↗ “In vivo experiments have documented the ability of vandetanib (ZD6474) to inhibit tumor growth in various preclinical tumor models.” NCT00995007 ↗ “This study will examine the effectiveness of an investigational drug called ZD6474 (also known as vandetanib or ZACTIMA).” NCT00566995 ↗ “Phase II Trial of Vandetanib (ZD6474, Caprelsa(R) in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors” NCT02015065 ↗ “This study uses the drugs Abraxane (also called ABI-007) and Vandetanib (also called Zactima and ZD6474).” NCT00667147 ↗ “ZD6474 (Vandetanib at the dose of 100 mg)” NCT00752986 ↗ “ZD6474 (vandetanib) 100mg” NCT00506051 ↗ |
| Action | Inhibit | “vandetanib, an inhibitor of vascular endothelial and epidermal growth factor receptors” PMID 17878480 ↗ Sep 20073“Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL24828 ↗ “Tyrosine-protein kinase BRK inhibitor” CHEMBL24828 ↗ “Tyrosine-protein kinase SRC inhibitor” CHEMBL24828 ↗ |
| Modality | Small molecule | “Vandetanib is a novel oral molecule (anilinoquinazoline)” NCT00687297 ↗ |
| Route | Oral | “300-mg Daily Oral Dose” NCT00034918 ↗ |
| Target | EGFR | “vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling” PMID 25881079 ↗ Mar 2015 |
| Target | PTK6 | “Tyrosine-protein kinase BRK inhibitor” CHEMBL24828 ↗ |
| Target | RET | “vandetanib, a selective inhibitor of VEGFR, RET and EGFR signaling” PMID 25881079 ↗ Mar 2015 |
| Target | SRC | “Tyrosine-protein kinase SRC inhibitor” CHEMBL24828 ↗ |
| Target | TEK | “Tyrosine-protein kinase TIE-2 inhibitor” CHEMBL24828 ↗ |